Mechanism and management of AKT inhibitor-induced hyperglycemia.
about
Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceManagement of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathwayPhase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinumMaximising the potential of AKT inhibitors as anti-cancer treatmentsAkt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunitiesGSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myelomaInterrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsRelieving autophagy and 4EBP1 from rapamycin resistance.Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancerClinical development of phosphatidylinositol-3 kinase pathway inhibitorsDNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.Akt inhibitors in clinical development for the treatment of cancer.The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy.Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials.Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumorsCell survival and metastasis regulation by Akt signaling in colorectal cancerThe use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor.Targeting the PI3K-AKT-mTOR signaling network in cancer.A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors.Impact of patient ethnicity on the metabolic and immunologic effects of PI3K-mTOR pathway inhibition in patients with solid tumor malignancies.Akt isoforms and glucose homeostasis - the leptin connection.The Biological Role of PI3K Pathway in Lung Cancer.Drug-Induced Hyperglycaemia and Diabetes.The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.Co-Managing Patients with Type 1 Diabetes and Cancer.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.AKT/PKB Signaling: Navigating the Network.Past and current perspective on new therapeutic targets for Type-II diabetes.Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinomaQuantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transport.The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant.
P2860
Q26775379-A504FBD6-C1E4-4F6E-9EF8-80EEA648398BQ27009375-9EFF2009-B774-4677-AB2E-D682362DB32DQ27851722-7E4050D9-AB7A-4282-B607-3C21B865E4CDQ28072254-57DA0287-DAC0-4361-9F7D-74AD34141598Q28080599-67894DD6-C1E4-4365-B492-E20EAA169646Q28397537-44588B3D-68B4-42C2-A844-71412CF7CA27Q33596707-B32A913A-0B2F-46FD-B11E-4B6F5FB326ADQ33882138-CA9483E4-08EB-4377-9D09-B5A1A18817A7Q34329614-1022F84E-468F-438F-835B-4DA6E439514CQ34500544-5463F64D-571A-4981-B8F6-1B616217DEC0Q34518245-675773E2-683A-4344-9034-D89C0452632AQ35051964-A606D1B7-87E2-420E-8C6E-176B709E18AFQ35096637-25AF6268-876E-42DC-9ACF-67EAA87109D5Q35256618-BBFEEF4C-0858-40A7-815B-0F2DA07E300FQ35566234-9C15C982-73BE-4D5C-BB0B-103FC4F2591DQ35571896-EFA356C0-606D-4A19-B42B-CC34652D109DQ35628576-9AD65418-04BF-495C-9434-B58FAC746635Q35911227-5DFC4410-90BE-44C1-82C0-C1E31D59FBA6Q36328064-3673B9A5-148E-4CC5-8218-AB40A1044EB3Q36443880-5488CF36-2FD3-49E1-9030-FBFA1C84FC1DQ36703783-B689017E-FC64-4F3D-8A96-B4F1EADE1CD8Q36762858-C0CBAC2B-64B8-4E2C-8BC9-185E69BBB09FQ36938826-9966670F-BAA1-44AD-9FFC-3F83B57EF131Q37167139-52A2ACC4-B872-4BED-AAFD-6370F4BD04C7Q37353968-0337AB0F-1497-4AFD-9A72-7F9F79E998C9Q37578324-41542409-8AB5-4739-BE84-61FE3BC81D99Q37600837-59BDDA7D-5373-4031-8ED9-82A7E05DEE18Q37800267-90867AFB-D73F-40D2-8168-A91C2989B3AEQ38166599-816818D4-DC4B-40CE-913F-E5EACA7DEE83Q38586781-E01FB144-DD64-4192-A0D2-A1D3CA7EC169Q38625610-421A3A22-41C1-470A-BFCB-D4714B53506AQ38869694-E5E89E88-B831-4710-996B-4CB8B0F60AD5Q38989374-72A105E3-324F-4C18-959A-3ACF34F7C7EDQ39040854-13A09020-65E2-4366-8036-0E3FE943F3EEQ39098904-2FA14141-A4F4-4A7E-A4A7-30F128E8963DQ39255027-EC1989F8-A8CE-4ACD-B721-FE2B9420CD7BQ39349756-01745F96-515F-4390-B58E-928AC88E610FQ41838545-3E1E70BB-80E9-46CA-ABDB-F9F59E5E9C41Q41858745-489848A5-5F3E-4C31-A6B6-1947D810D589Q42424800-DED453D3-01EA-4D3B-AE5D-F40755DD809E
P2860
Mechanism and management of AKT inhibitor-induced hyperglycemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Mechanism and management of AKT inhibitor-induced hyperglycemia.
@en
Mechanism and management of AKT inhibitor-induced hyperglycemia.
@nl
type
label
Mechanism and management of AKT inhibitor-induced hyperglycemia.
@en
Mechanism and management of AKT inhibitor-induced hyperglycemia.
@nl
prefLabel
Mechanism and management of AKT inhibitor-induced hyperglycemia.
@en
Mechanism and management of AKT inhibitor-induced hyperglycemia.
@nl
P2093
P1476
Mechanism and management of AKT inhibitor-induced hyperglycemia.
@en
P2093
Derek J Eberwein
Gobalakrishnan Sundaresan
Jason A Kahana
Kathleen K Brown
Ming-Chih Crouthamel
Rakesh Kumar
Shu-Yun Zhang
Susan Korenchuk
P304
P356
10.1158/1078-0432.CCR-08-1253
P407
P577
2009-01-01T00:00:00Z